A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

AIMS/HYPOTHESIS: Numerous clinical studies have investigated the anti-CD3ɛ monoclonal antibody otelixizumab in individuals with type 1 diabetes, but limited progress has been made in identifying the optimal clinical dose with acceptable tolerability and safety. The aim of this study was to evaluate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetologia
Main Authors: Keymeulen, Bart, van Maurik, André, Inman, Dave, Oliveira, João, McLaughlin, Rene, Gittelman, Rachel M., Roep, Bart O., Gillard, Pieter, Hilbrands, Robert, Gorus, Frans, Mathieu, Chantal, Van de Velde, Ursule, Wisniacki, Nicolas, Napolitano, Antonella
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7801303/
https://ncbi.nlm.nih.gov/pubmed/33145642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-020-05317-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados